This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.CW Shepard , L Finelli , MJ Alter . Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases 2005; 5: 558–567.
2.World Health Organisation.Hepatitis C: global prevalence. Weekly Epidemiological Record 1997; 72: 341–344.
3.GM Lauer , BD Walker . Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 41–52.
4.MP Manns , The way forward in HCV treatment-finding the right path. Nature Reviews Drug Discovery 2007; 6: 991–1000.
5.J Thompson-Coon , Case finding for hepatitis C in primary care: a cost utility analysis. Family Practice 2006; 23: 393–406.
6.GR Foster , Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. British Medical Journal 1997; 315: 453–458.
8.MEE Kretzschmar .The prevalence of hepatitis C in the Netherlands [in Dutch]. Bilthoven, the Netherlands, National Institute of Public Health and the Environment, 2004; publication number VWS-IGZ 2004/02 – Project V/210041.
9.A Kok , Hepatitis C in the Netherlands: sparse data on the current prevalence and the necessity for epidemiological studies and innovative methods for detecting infected individuals [in Dutch]. Nederlands Tijdschrift voor Geneeskunde 2007; 151: 2367–2371.
11.MJ de Vries , B te Rijdt , CM van Nieuwkerk . Transmission of hepatitis C genotypes in the Netherlands amongst recently genotyped patients. Netherlands Journal of Medicine 2008; 66: 40–41.
12.C Frank , The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–891.
13.MI Meltzer . Introduction to health economics for physicians. Lancet 2001; 358: 993–998.
14.CW Helsper , A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Family Practice 2010; 27: 328–332.
17.U Siebert , Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–432.
19.B Smyth , J Fan , YI Hser . Life expectancy and productivity loss among narcotics addicts thirty-three years after index treatment. Journal of Addictive Diseases 2006; 25: 37–47.
20.Organisation for Economic Cooperation and Development (OECD). Health Data 2007 (CD-ROM), 2007.
24.E Op de Coul , A Bosman , M van de Laar . Surveillance of hepatitis C in the Netherlands, 1992–2002 [in Dutch]. Infectieziekten Bulletin 2003; 9: 323–328.
25.DJ de Jong , Referral of hepatitis C virus seropositive patients in primary care in the Netherlands. Netherlands Journal of Medicine 2008; 66: 42–43.
27.Statistics Netherlands (CBS)
. CBS table: Population per region subdivided to country and gender Database (http://statline.cbs.nl/StatWeb/
). Accessed 1 January 2006.
29.E Castelnuovo , The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment 2006; 10: xiii–iv, ix–xii, 1–93.
30.K Stein , Screening for hepatitis C in injecting drug users: a cost utility analysis. Journal of Public Health (Oxford) 2004; 26: 61–71.
31.G Sroczynski , Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. European Journal of Public Health 2009; 19: 245–253.
33.JMG Wilson , G Jungner . Principles and practice of mass screening for disease. Boletín de la Oficina Sanitaria Panamericana 1968; 65: 281–393.
34.A Andermann , Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008; 86: 317–319.
35.IK Veldhuijzen , Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138: 522–530.
36.AD Paltiel , Expanded screening for HIV in the United States – an analysis of cost-effectiveness. New England Journal of Medicine 2005; 352: 586–595.
37.SA Bozzette . Routine screening for HIV infection-timely and cost-effective. New England Journal of Medicine 2005; 352: 620–621.
38.V Soriano , MG Peters , S Zeuzem . New therapies for hepatitis C virus infection. Clinical Infectious Diseases 2009; 48: 313–320.
39.S Zeuzem . Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & Hepatology 2008; 5: 610–622.